IFOM Publications Claudio Vernieri

Publications Claudio Vernieri

Selected publications

  1. Vernieri C, Ganzinelli M, Rulli E, Farina G, Bettini AC, Bareggi C, Rosso L, Signorelli D, Galli G, Lo Russo G, Proto C, Moro M, Indraccolo S, Busico A, Sozzi G, Torri V, Marabese M, Massimo B, Garassino MC; TAILOR trialists.
    LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
    ESMO Open. 2020 May;5(3):e000748. doi: 10.1136/esmoopen-2020-000748. PMID: 32467099 - Free article.

  2. D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, Vernieri C, Di Giacinto F, Bernassola F, de Braud F, Lucibello M.
    DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.
    Cells. 2020 May 19;9(5):E1260. doi: 10.3390/cells9051260. PMID: 32438775 - Free article.

  3. Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD.
    Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers.
    Nat Commun. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3. PMID: 32393788 Free PMC article.

  4. Mirabile A, Rivoltini L, Daveri E, Vernieri C, Mele R, Porcu L, Lazzari C, Bulotta A, Viganò MG, Cascinu S, Gregorc V.
    Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.
    Cancers (Basel). 2020 May 4;12(5):E1153. doi: 10.3390/cancers12051153. PMID: 32375310 Free article. Review.

  5. Vernieri C, Corti F, Nichetti F, Ligorio F, Manglaviti S, Zattarin E, Rea CG, Capri G, Bianchi GV, de Braud F.
    Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Breast Cancer Res. 2020 Apr 6;22(1):33. doi: 10.1186/s13058-020-01271-0. Review. PMID: 32252811

  6. Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F.
    Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
    Cancers (Basel). 2020 Mar 6;12(3). pii: E617. doi: 10.3390/cancers12030617. PMID: 32155941

  7. Castagnoli L, De Santis F, Volpari T, Vernieri C, Tagliabue E, Di Nicola M, Pupa SM.
    Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.
    Cells. 2020 Feb 27;9(3). pii: E555. doi: 10.3390/cells9030555. Review. PMID: 32120774

  8. Kong WJ, Vernieri C, Foiani M, Jiang JD.
    Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
    Pharmacol Ther. 2020 Jan 27:107496. doi: 10.1016/j.pharmthera.2020.107496. [Epub ahead of print] Review. PMID: 32001311

  9. Vernieri C, Pusceddu S, de Braud F.
    Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors.
    Front Oncol 2019;9:902

  10. Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C et al.
    Weighing the prognostic role of hyponatriemia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study.
    Sci Rep 2019;9(1):12993. PMID: 31506579

  11. Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, et al.
    Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
    Cell Oncol (Dordr) 2019. PMID: 31376137

  12. Rivoltini L, Vernieri C, Huber V.
    The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer.
    Cancer Res. 2019;79(13):3169-3171. PMID: 31262832

  13. Vernieri C, Milano M, Brambilla M, et al.
    Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives.
    Critical Reviews in Oncology/Hematology 2019;139:53-66. PMID: 31112882.

  14. Corno A, Chiroli E, Gross F, Vernieri C, et al.
    Cellular response upon proliferation in the presence of an active mitotic checkpoint.
    Life Science Alliance 2019;2(3). PMID: 31068378

  15. Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, et al.
    Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    ESMO Open 2019;4(1). PMID: 30964126

  16. Cona MS, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A, Poggi MM, Raggi D, Randon G, Ratta R, Signorelli D, Vernieri C, et al.
    Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
    Cancers (Basel) 2019 Feb 14;1(2). PMID: 30769874

  17. Vernieri C, Prisciandaro M, Milano M, et al.
    Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
    Clin Breast Cancer 2019;19(2):e306-e318. PMID: 30635175

  18. Vernieri C, Signorelli D, Galli G, et al.
    Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
    Clin Lung Cancer 2019;20(3)e413-e417. PMID 30617039

  19. Vernieri C, Galli F, Ferrari L, et al.
    Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
    Oncologist 2019;24(3):385-393. PMID: 30606884

  20. Vernieri C, Pusceddu S, Fucà G, et al.
    Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
    Int J Cancer 2019;144(7):1704-1712. PMID: 30520016

  21. Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud FG, Vernieri C, et al.
    Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    J Thorac Oncol 2018;13(11):1692-1704. PMID: 30149143

  22. Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, et al.
    Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
    J Cell Physiol 2019; 234(2):1768-1779. PMID: 30132876

  23. Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D.
    Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.
    Ann Surg. 2018 Jul 10. PMID: 29995678

  24. Vernieri C, Mennitto A, Prisciandaro M., et al.
    The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
    Sci Rep. 2018 Jun 7;8(1):8703. PMID: 29880896

  25. Pusceddu S, Vernieri C et al.
    Metformin Use Associates With Longer Progression-free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Gastroenterology 2018;155(2):479-489. PMID: 29655834

  26. Pusceddu S, Barretta F, Trama A, Botta L, Milione M et al.
    A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
    Endocr Relat Cancer. 2018 Jun;25(6):607-618. PMID: 29559553

  27. Vernieri C, Nichetti F et al.
    Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives
    Crit Rev Oncol Hematol. 2018 Mar;123:57-73. PMID: 29482780

  28. Bonaiuti P, Chiroli E, Gross F, Corno A, Vernieri C et al.
    Cells Escape an Operational Mitotic Checkpoint through a Stochastic Process.
    Curr Biol. 2018 Jan 8;28(1):28-37.e7. PMID: 29249657

  29. Oddo D, Siravegna G, Gloghini A, Vernieri C et al.
    Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
    Br J Cancer. 2017 Jul 25;117(3):347-352. PMID: 28654634

  30. Vernieri C, Milano M, Mennitto A et al.
    Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, moncentric, retrospective study.
    Breast Cancer Res Treat. 2017 Sep;165(2):365-373. PMID: 28616768

  31. Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F.
    Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
    Future Oncol. 2017 Aug;13(19):1677-1683. PMID: 28580793

  32. Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G.
    Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
    Ther Adv Med Oncol. 2017 Mar;9(3):183-188. PMID: 28344663

  33. Vernieri C, Casola S, Foiani M, et al:
    Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.
    Cancer Discovery 2016;6(12):1315-1333. PMID: 27872127

  34. Pietrantonio F, Vernieri C, Siravegna G, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res 2017;23(10:2414-2422. PMID: 27780856

  35. Pusceddu, S., Buzzoni, R., Vernieri, C. et al.
    Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Future Oncol 2016;12(10):1251-60. PMID: 26890290.

  36. Crespo, C. L., Vernieri, C. et al.
    The PAR complex controls the spatiotemporal dynamics of F-actin and the MTOC in directionally migrating leukocytes.
    J Cell Sci 2014;127:4381-4395. PMID: 25179599.

  37. Vernieri, C., Chiroli, E., Francia, V., Gross, F. & Ciliberto, A
    Adaptation to the spindle checkpoint is regulated by the interplay between Cdc28/Clbs and PP2ACdc55.
    J Cell Biol 2013;202, 765-778. PMID: 23999167

  38. Santaguida S, Vernieri C, Villa F, Ciliberto A, Musacchio A.
    Evidence that Aurora B is implicated in spindle checkpoint signaling independently or error correction.
    EMBO J. 2011 Apr 20;30(8):1508-19. PMID: 21407176

Uptade: Apr 2020